ProCE Banner Activity

CE / CME

HABP/VABP: Strategies for Early Effective Therapy in Critically Ill Patients

Video

In this on-demand webcast from a live symposium at SCCM 2023, expert faculty discuss key concepts of antimicrobial resistance and risk stratification in HABP/VABP, treatment of difficult-to-treat pathogens, and considerations for antimicrobial dose optimization in unique clinical scenarios (eg, augmented or diminished renal clearance) through case-based discussion.

Registered Nurses : 1.00 Nursing contact {hour}

Pharmacists : 1.00 contact {hour} ({0.1} CEUs)

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Released: March 20, 2023

Expiration: March 19, 2024

No longer available for credit.

Share

Faculty

Monica Donnelley

Monica Donnelley, PharmD, BCIDP, BCPS, AAHIVP

Clinical Pharmacist Specialist, Infectious Diseases
Infectious Diseases Residency Program Director 
Assistant Clinical Professor
Touro University, College of Pharmacy
UC Davis School of Medicine
UCSF School of Pharmacy
Department of Pharmacy Services
UC Davis Health System
Sacramento, California

Christian Sandrock

Christian Sandrock, MD, MPH, FCCP

Vice Chair for Inpatient Care
Associate Chief Medical Officer, UC Davis Health
Division of Pulmonary, Critical Care and Sleep Medicine
UC Davis Medical Center
Professor of Medicine
University of California Davis School of Medicine
Sacramento, California

Provided by

ProCE Banner

Supporters

AbbVie

Partners

ProCE, LLC

ProCE Banner

Society of Infectious Diseases Pharmacists (SIDP)

ProCE Banner

Target Audience

The target audience comprises physicians, pharmacists, nurses, and other HCPs who care for critically ill patients with HABP/VABP.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of HCPs in optimizing individualized care and antimicrobial management for patients with HABP/VABP with suspected or documented antimicrobial resistance.

Learning Objectives

After completing this activity, participants should be better able to:

  • Describe recent epidemiologic patterns and threat levels of bacterial resistance and the associated burden on the healthcare system and clinical practice

  • Differentiate available antimicrobial agents for difficult-to-treat pathogens in HABP/VABP, including efficacy, safety, pharmacokinetics/ pharmacodynamics, and activity in the setting of key resistance mechanisms

  • Optimize antimicrobial agents for the treatment of HABP/VABP in critically ill patients, including unique clinical scenarios, such as augmented or diminished renal clearance

  • Develop strategies to minimize TTET while incorporating the latest clinical guidelines, patient-specific factors, and antimicrobial stewardship principles

Disclosure

The Society of Critical Care Medicine (SCCM) require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to SCCM policy.

SCCM is committed to providing its learners with high-quality CE/ACE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Monica Donnelley, PharmD, BCIDP, BCPS, AAHIVP, has no relevant financial relationships to disclose.

Christian Sandrock, MD, MPH, FCCP: advisor/speaker/honoraria: AbbVie, Paratek, Shionogi; clinical trial investigator: Johnson & Johnson.

The planners and content peer reviewers from SCCM; ProCE, LLC; and the Society of Infectious Disease Pharmacists (SIDP) do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.00 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from 02/22/2023, through 02/21/2024:

  1. Create an account or Login at https://proce.com
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online.

 You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of SCCM and ProCE. The Society of Critical Care Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement
The Society of Critical Care Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim credit commensurate with the extent of their participation in the activity. 

Nurses
The Society of Critical Care Medicine is approved by the California Board of Registered Nursing, Provider No. 8181, for 1.0 contact hour.

Pharmacists

The Society of Critical Care Medicine is accredited by the Accredication Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy credit.

This home study activity will provide 1.0 continuing education hour.